Human Coagulation Factor VII Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB23381
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Ala39-Pro444
Accession # NP_062562
Specificity
Clonality
Host
Isotype
Scientific Data Images for Human Coagulation Factor VII Antibody
Detection of Coagulation Factor VII in HASMC Human Cells by Flow Cytometry.
HASMC human aortic smooth muscle cells were stained with Mouse Anti-Human Coagulation Factor VII Monoclonal Antibody (Catalog # MAB23381, filled histogram) or isotype control antibody (Catalog # MAB0041, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG F(ab')2Secondary Antibody (Catalog # F0102B).Applications for Human Coagulation Factor VII Antibody
CyTOF-ready
Flow Cytometry
Sample: HASMC human aortic smooth muscle cells
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: Coagulation Factor VII
Coagulation Factors VII and VIIa refer to the pro and active forms of the same protease, respectively (1). Factor VII is synthesized in the liver and circulates in the plasma where it binds to tissue factor (TF), an integral membrane protein found in a variety of cell types. Upon binding of TF, Factor VII is rapidly converted into VIIa. The resulting 1:1 complex of VIIa and TF initiates the coagulation pathway and has also important coagulation-independent functions such as angiognesis (2). The cleavage and activation of Coagulation Factors VII, IX and X by VIIa:TF is phospholipid-dependent whereas the cleavage of small peptide substrates is not (1). The predominant splicing variant of Factor VII in normal liver corresponds to the 444 amino acid precursor (3, 4). After a signal peptide (residues 1-38), the mature chain can be further processed into the light chain (residues 39-190) and the heavy chain (residues 191-444). The purified rhFactor VII corresponds to the mature chain, which can be processed and activated by treatment with thermolysin and binding with rhTissue Factor (R&D Systems, Catalog # 2339-PA) under the conditions described above.
References
- Morrissey, J.H. (2004) in Handbook of Proteolytic Enzymes, Barrett, A.J. et al. eds. p. 1659.
- Versteeg, H.H. et al. (2003) Carcinogenesis 24:1009.
- Hagen, F.S. et al. (1986) Proc. Natl. Acad. Sci. USA 83:2412.
- O’Hara, P.J. et al. (1987) Proc. Natl. Acad. Sci. USA 84:5158.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional Coagulation Factor VII Products
Product Documents for Human Coagulation Factor VII Antibody
Product Specific Notices for Human Coagulation Factor VII Antibody
For research use only